60 results about "CD40" patented technology

This invention relates to anti-CD40 antibodies or antigen-binding fragments thereof that specifically recognize and weakly activate CD40 molecules in humans, cynomolgus monkeys, and mice, as well as immunoconjugates, pharmaceutical compositions, and combination products comprising said anti-CD40 antibodies or antigen-binding fragments thereof. The invention also relates to nucleic acids encoding said anti-CD40 antibodies or antigen-binding fragments thereof and host cells comprising said nucleic acids, and methods for preparing said anti-CD40 antibodies or antigen-binding fragments thereof. Furthermore, the invention relates to the use of said anti-CD40 antibodies or antigen-binding fragments thereof in the prevention or treatment of tumors or infectious diseases in subjects.

The invention discloses a fusion protein linked with CD40-expressing cells containing APC and target specific T cells and application thereof, CD40L and other elements combined with CD40 are fused with target antigens specifically recognized by molecules in cells such as CAR-T or TCR-T to form a bifunctional protein, the DC maturation of the CD40L and other elements combined with CD40 can be enhanced, and meanwhile, the CD40L and other elements combined with CD40 can be combined with the target antigens specifically recognized by the molecules in the cells such as CAR-T or TCR-T to form the bifunctional protein, so that the CD40L and other elements combined with CD40 can be combined with the target antigens specifically recognized by the molecules in the cells. The target antigen is effectively delivered to the surface of the DC, so that the activation effect of the DC on cells such as CAR-T or TCR-T is enhanced, and particularly, the effect of enhancing the functions such as terminal amplification and reverse depletion of the cells such as CAR-T or TCR-T is remarkable.

There is an urgent need for an effective therapeutic vaccine against tuberculosis (TB), which remains a major public health problem. Current "classical" strategies under development have failed or are suboptimal, and more effective vaccines are needed to achieve the World Health Organization's 2035 End TB Strategy. We have generated a post-exposure / therapeutic TB vaccine candidate (CD40.TB) whose heavy chain consists of an antibody directed against a surface antigen (i.e., CD40) of antigen-presenting cells (i.e., dendritic cells) conjugated to three relevant Mycobacterium tuberculosis (Mtb) antigens and which is liable to induce potent anti-TB humoral and cellular immunity.

Provided herein are oncolytic viruses containing payload genes, including genes encoding IL-12, FLT3L, CD40 agonists, and / or CTLA-4 antibodies. Expression cassettes, pharmaceutical compositions, and methods of treatment using these viruses are also provided. Additionally, expression cassettes and CD40 agonist molecules are also provided in the present disclosure.

The present invention relates to combination therapies for treating cancer, optionally chemotherapy-resistant cancers, in a subject. The combination therapies comprise (a) an antibody or antigen-binding portion thereof that specifically binds to CD40, and (b) chemotherapy. The invention also relates to pharmaceutical compositions, kits and methods of using such therapies.

The invention provides a nucleic acid aptamer, and the nucleotide sequence of the nucleic acid aptamer is as shown in SEQ ID No: 1, or a sequence having 80% or more of identity with the nucleotide sequence. The nucleic acid aptamer successfully screened out in the invention has good affinity and specificity with CD40, and the binding capacity of the nucleic acid aptamer can be comparable with that of an antibody. In the functional level, the nucleic acid aptamer can be effectively combined with DC2.4 cells expressing CD40 and up-regulate the expression of related genes; the compound also shows remarkable immunostimulatory activity in an animal model, and shows a synergistic effect when being combined with an immunostimulant. The invention provides an important basis for subsequent development and transformation application of the CD40 nucleic acid aptamer, and also provides a new candidate tool and technical support for drug research and development based on a CD40 target spot.

Disclosed herein are monospecific and multispecific antibodies specific for CD28 and CD3E, and one or more of OX-40, CD40, 4-1BB, HSA, IL-22, PD-L1, CD16, CD47, CD33, LAG3, and EGFR.

The present invention relates to the technical field of molecular biology, and in particular, to an anti-CD40 nanobody, and a preparation method therefor and use thereof. The anti-CD40 nanobody provided by the present invention has three unique complementarity determining regions, namely CDR1, CDR2, and CDR3. The present invention further provides a sequence encoding the nanobody or its VHH chain, a corresponding expression vector, and a host cell capable of expressing the nanobody. The present invention includes immunizing an alpaca by constructing a CD40 antigen to obtain a PBMC of the alpaca and constructing a vector; screening an anti-CD40 antibody through phage display; and finally obtaining a highly sensitive and specifically binding antibody through functional assays and sequencing result analysis. The nanobody provided by the present invention can specifically recognize and bind to CD40.

The present invention relates to the field of pharmaceutical formulations, and provides a formulation of an anti-CD40L antibody and a preparation method for the formulation. More specifically, the present invention provides a formulation of a recombinant humanized anti-cluster of differentiation antigen CD40 ligand (CD40L) antibody and a preparation method for the formulation, and also relates to a use of the formulation in treating diseases or conditions related to inappropriate activation of a CD40L / CD40 mediated pathway.

The present disclosure provides antigen binding molecules that bind to CD40, such as bispecific antigen binding molecules that bind to two different epitopes of CD40. In some embodiments, the antigen binding molecules inhibit CD40L-induced activation and do not significantly agonize CD40 in the absence of CD40L. Also provided are methods for treating CD40 mediated diseases using the antigen binding molecules.

The application of the biomarker combination in the preparation of a drug for fulminant myocarditis belongs to the field of drugs. The application is characterized in that the biomarker combination comprises Siglec-5; the biomarker combination is further selected from the group consisting of sST2, PAI-1, Siglec-5, CD163, CD40, P-Cadherin, CD14, CTLA4. The application finds that the expression of the biomarker in the plasma of a patient with fulminant myocarditis is increased, and confirms the role of the biomarker as a drug target in relieving and / or improving fulminant myocarditis. The level of the biomarker can be controlled by a drug, the diagnosis and subsequent treatment of the disease can be more intensified, and the biomarker has great application value in clinical practice.

The present invention provides immunostimulatory nucleic acids that have an affinity to a specific target protein. The present invention also provides templates and methods for making and using the immunostimulatory nucleic acids. Further, methods for linking the immunostimulatory nucleic acids to antigens and using the resulting complexes to enhance an immune response are provided.

The present disclosure provides antibodies that bind to CD40, and methods of using them to modulate immunity in a patient in need thereof and to treat autoimmune disorders or immunoinflammatory disorders.

A pharmaceutical composition of a FAP / CD40 binding molecule and its pharmaceutical use. Specifically, the pharmaceutical composition comprises a FAP / CD40 binding molecule and a buffering agent. The pharmaceutical composition has good biological activity and stability.

The application discloses a method for inducing Breg cell proliferation in vitro. The method comprises the following steps: (1) culturing B cells derived from mammals in a culture medium containing CD40 antibodies; (2) adding SARS-CoV-2 virus antigens to the culture system, wherein the SARS-CoV-2 virus antigens are selected from one or more of N protein, S protein specific epitope peptide segments or S1 subunits containing RBD regions of S protein; and (3) after 24-96 hours of culture, the induction of Breg cells is achieved. The application uses SARS-CoV-2 specific protein antigens to significantly improve the proportion of B cell conversion to Breg cells, and realizes the specific induction of Breg (CD19 + IL-10 + ) cell proliferation and differentiation under in vitro conditions.

The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.

Disclosed herein are multivalent, multispecific single-chain antibodies having specificity for four antigens selected from the group consisting of EGFR, PD-L1, HSA, CD28, CD3E, OX-40, CD40, 4-1BB, LAG3, and CD16A.

Provided herein are bispecific antigen-binding molecules that bind to PD-L1 and / or CD40. Further provided herein are therapeutic uses and methods of producing such molecules, as well as related pharmaceutical compositions, nucleic acid molecules, expression vectors, and host cells.

The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.

This document discloses antibodies targeting CD40 and their uses. It also discloses novel antigen-binding proteins capable of specifically binding to CD40 and their antigen-binding fragments. Furthermore, this document discloses fusion proteins comprising a first domain activating antigen-presenting cells (APCs) (e.g., dendritic cells) and a second domain activating immune effector cells (e.g., T cells), wherein the first domain comprises the antigen-binding protein or its antigen-binding fragment that specifically binds to CD40 disclosed herein.

The present invention relates to FAP / 4-1BB / CD40 binding molecules and pharmaceutical uses thereof, particularly FAP / 4-1BB / CD40 binding molecules, 4-1BB binding molecules, polynucleotides encoding the binding molecules, vectors, pharmaceutical compositions, and methods for treating cancer and related pharmaceutical uses thereof.

Provided herein are methods and compositions for treating kidney-related disease conditions and complications, such as Berger's disease, and for preventing transplant rejection. For example, the present disclosure describes a method of improving function of a transplanted kidney in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds CD40 ligand.

The present invention relates to an in vitro method for culturing one or more antibody-expressing cells. The method comprises culturing one or more antibody-expressing cells obtained from peripheral blood in the presence of IL-2, IL-21, and non-cell surface-presented CD40 stimulants and in the absence of feeder cells. Furthermore, this specification provides a method for producing antibodies, including the step of culturing one or more antibody-expressing cells according to the method of the present invention, novel CD40 stimulants and their use, and cell culture media.

The application belongs to the field of biological products, and particularly relates to an antagonistic anti-CD40 antibody and a preparation method and application thereof. The antagonistic anti-CD40 antibody is H-CD40-ab-DYS-4 nanobody. The antagonistic anti-CD40 antibody has a better effect on inhibiting the proliferation rate of B cells than a commercially available anti-CD40L monoclonal antibody hu5c8, which provides a broad prospect for the application of the antagonistic anti-CD40 antibody to autoimmune diseases and inhibition of immune rejection reactions of organ transplantation.

The invention provides a combined composition containing cell factors with immunomodulatory effects, such as modified IL-2 molecules or IL-7, IL-12, IL-15, IL-18, IL-21 and the like, and a CD40 agonistic antibody. The tumor growth inhibition rate of the combined composition after combined use is obviously superior to that of any single drug. The combined composition provided by the invention has an obvious anti-tumor synergistic effect.

A pharmaceutical composition of a FAP / CD40 binding molecule and the pharmaceutical use thereof. Specifically, the pharmaceutical composition contains a FAP / CD40 binding molecule and a buffer agent. The pharmaceutical composition has a good biological activity and stability.

Disclosed are an antigen-binding protein targeting PD-L1 and CD40, preparation therefor, and use thereof. The antigen-binding protein targeting PD-L1 and CD40, by means of blocking a PD-1 / PD-L1 inhibitory signaling pathway, acting on an activated CD40 receptor, and simultaneously activating an antigen-presenting cell and a lymphocyte, achieves a significant synergistic anti-tumor effect; meanwhile, the activation of the antigen-binding protein targeting PD-L1 and CD40 on an immune cell only occurs at a tumor microenvironment site, so that problems of systemic drug toxicity and side effects are significantly solved, which enables the antigen-binding protein targeting PD-L1 and CD40 to exert an excellent anti-tumor efficacy under very safe conditions.

CD40 activating proteins comprising recombinant proteins with CD40 agonist antibodies or their antigen-binding fragments fused or linked to CD40 ligand are provided. The CD40 activating proteins may further comprise at least one antigen. Uses for the CD40 activating proteins include inducing immune responses directed to delivered antigens such as viral or cancer antigens. Properties of the CD40 activating protein may include the ability to induce proliferation of B cells or secretion of cytokines, such as IL-6, IL-12 and / or IL-15.

The present invention relates to an in vitro method for cultivating one or more antibody expressing cell(s). The method comprises cultivating one or more antibody expressing cell(s) obtained from peripheral blood in the presence of IL-2, IL-21 and a non-cell surface presented CD40-stimulating agent and in the absence of feeder cells. Moreover, herein provided are methods for producing antibodies comprising the step of cultivating one or more antibody expressing cell(s) according to the method of the invention, a novel CD40-stimulating agent and uses therefrom as well as a cell culture medium.